KNTE のPB 比率は同業他社と比較してどうか。

KNTEは、同業他社の平均 ( { 0.8 x) と比較したPrice-To-Book比率 ( 1.4 x) に基づいて価値が高いといえます。

KNTE'のPB レシオは、US Biotechs 業界の他社と比較してどうか。

KNTEは、 US Biotechs業界平均 (1.9x) (0.8 x) と比較したPrice-To-Book比率 ( 1.9 x) に基づいて価値が高いといえます。

KNTE'のPB レシオとフェアPB レシオを比較すると？これは、会社の予想利益成長率、利益率、その他のリスク要因を考慮した予想PB レシオです。

評価分析のためのKNTEのPrice-To-Book公正比率を計算するにはデータが不十分です。

KNTE 、その将来キャッシュフローを見たときの公正価格はいくらになるだろうか？この見積もりには、割引キャッシュフローモデルを使用します。

評価分析のためのKNTEの公正価値を計算するためのデータが不十分です。

アナリストの12ヶ月の予想と、コンセンサス目標株価に対する統計的信頼性は？

目標株価は現在の株価よりも低いです。

Kinnate Biopharma ( ) - 株価, ニュースと分析Nasdaq:KNTE

Q: アナリストの12ヶ月の予想と、コンセンサス目標株価に対する統計的信頼性は？

目標株価は現在の株価よりも低いです。

KNTE 株式概要

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. 詳細

KNTE ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	6/6
配当金	0/6

リスク分析

収益が 100 万ドル未満 ( $0 )

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

Kinnate Biopharma Inc. 競合他社

Pyxis Oncology

NasdaqGS:PYXS

US$113.0m

Seres Therapeutics

NasdaqGS:MCRB

US$131.2m

Decibel Therapeutics

NasdaqGS:DBTX

US$124.3m

Repare Therapeutics

NasdaqGS:RPTX

US$119.5m

価格と性能

の歴代最高値、変動、値下がりまとめKinnate Biopharma
過去の株価
現在の株価	US$2.65
52週高値	US$7.19
52週安値	US$1.04
ベータ	1.34
11ヶ月の変化	2.32%
3ヶ月変化	6.43%
1年変化	-56.84%
33年間の変化	-90.86%
5年間の変化	n/a
IPOからの変化	-93.21%

Recent updates

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Aug 11

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

May 15

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Jan 24

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Oct 09

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Jun 22

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Mar 03

Kinnate Biopharma earns bulls as IPO quiet period ends

Dec 28

株主還元

	KNTE	US Biotechs	US 市場
7D	-0.4%	2.5%	2.2%
1Y	-56.8%	16.1%	31.6%

業界別リターン: KNTE過去 1 年間で16.1 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: KNTEは、過去 1 年間で31.6 % のリターンを上げたUS市場を下回りました。

価格変動

Is KNTE's price volatile compared to industry and market?
KNTE volatility
KNTE Average Weekly Movement	5.8%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

安定した株価: KNTE過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: KNTEの週次ボラティリティは、過去 1 年間で14%から6%に減少しました。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2018	94	Nima Farzan	www.kinnate.com

Kinnate Biopharma Inc. 基礎のまとめ

Kinnate Biopharma の収益と売上を時価総額と比較するとどうか。
KNTE 基礎統計学
時価総額	US$125.15m
収益（TTM）	-US$112.65m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-1.1x

PER（株価収益率

KNTE は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
KNTE 損益計算書（TTM）
収益	US$0
売上原価	US$0
売上総利益	US$0
その他の費用	US$112.65m
収益	-US$112.65m

直近の収益報告

Dec 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-2.39
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	0%

KNTE の長期的なパフォーマンスは？

過去の実績と比較を見る

KNTE 株式概要

リスク分析

Kinnate Biopharma Inc. 競合他社

NasdaqGS:PYXS

US$113.0m

NasdaqGS:MCRB

US$131.2m

NasdaqGS:DBTX

US$124.3m

NasdaqGS:RPTX

US$119.5m

価格と性能

最新ニュース

Kinnate Biopharma Files Form 15

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index

Price target increased by 21% to US$4.53

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Price target decreased by 84% to US$3.75

Recent updates

Kinnate Biopharma Files Form 15

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index

Price target increased by 21% to US$4.53

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Price target decreased by 84% to US$3.75

Insufficient new directors

Kinnate Biopharma Inc. Announces Workforce Restructuring

New minor risk - Market cap size

Price target increased by 8.1% to US$25.86

Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

Price target decreased by 16% to US$25.00

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Kinnate Biopharma Inc. Appoints Jill DeSimone as Independent Director, Effective on March 1, 2023

Kinnate Biopharma Inc. to Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Price target decreased to US$31.88

High number of new and inexperienced directors

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Kinnate Biopharma Inc. Announces Pipeline Update

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from Russell 2000 Growth Index

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

Price target decreased to US$40.71

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

High number of new and inexperienced directors

Kinnate Biopharma Inc., Annual General Meeting, Jun 10, 2022

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Its FGFR Inhibitor Product Candidate, KIN-3248

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Price target decreased to US$43.43

Chief Medical Officer recently bought US$339k worth of stock

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation At the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Kinnate Biopharma Inc. Announces U.S Food and Drug Administration Clearance of Investigational Drug Application for KIN-3248

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Kinnate Biopharma Inc. Announces That the First Patient Has Commenced Treatment in its Phase 1 KN-8701 Clinical Trial

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Director Stephen Kaldor has left the company

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

New 90-day low: US$29.70

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Kinnate Biopharma earns bulls as IPO quiet period ends

Kinnate Biopharma Inc. has completed an IPO in the amount of $240 million.

株主還元

価格変動

会社概要

Kinnate Biopharma Inc. 基礎のまとめ

0.0x

-1.1x

収益と収入